Radioactive Iodine Therapy: What It Is, Who Needs It, and Why the Answer Is Not Always Clear
Written by John P. Sabra, MD FACS
Updated May 2026
Educational only. This article is not medical advice. Always consult your physician about your individual situation.
Radioactive iodine is one of the most debated topics in thyroid cancer care. Whether a patient needs it after surgery is rarely a simple yes or no, and the decision often comes down to the judgment of an experienced endocrinologist who knows the complete picture.
What Radioactive Iodine Actually Does
Radioactive iodine, known as RAI or I-131, is a treatment given to some patients after thyroid surgery for cancer. Because thyroid cells are one of the very few tissue types in the body that actively absorb iodine, a radioactive form can be used to selectively destroy any remaining thyroid tissue — including cancer cells that may have spread to lymph nodes or other locations. RAI is taken orally as a capsule or liquid, typically four to six weeks after total thyroidectomy. RAI is not chemotherapy and does not suppress the immune system.
Who Clearly Benefits and Who Does Not
The clearest benefit of RAI is in patients with higher-risk thyroid cancer: larger tumors, spread to multiple lymph nodes, evidence of distant metastasis, or more aggressive histologic types. For these patients the recommendation is generally not controversial.
At the other end, the evidence is equally clear that RAI adds no benefit for very low-risk thyroid cancer: small papillary microcarcinomas confined entirely within the thyroid with no lymph node involvement. Multiple studies and updated American Thyroid Association guidelines have moved strongly against routine RAI in this group.
The middle ground is where the genuine controversy lives. For intermediate-risk patients, the decision about RAI is one of the most debated topics in thyroid cancer management, with expert endocrinologists regularly reaching different conclusions from the same set of facts.
The intermediate-risk category includes patients with small lymph node involvement, minor extrathyroidal extension, or intermediate-sized tumors without clearly high-risk features. For these patients, the data on whether RAI reduces recurrence is genuinely mixed — some studies show benefit, others do not. This is not a failure of medicine. It is an honest reflection of scientific uncertainty, and it means that a thoughtful endocrinologist who recommends RAI and one who does not may both be making defensible, evidence-informed decisions.
Who Makes This Decision and How
The RAI decision is typically made by the endocrinologist managing post-surgical care, in consultation with the thyroid surgeon and sometimes a nuclear medicine physician. It is not a surgical decision. Factors include tumor size, completeness of surgical resection, number and size of involved lymph nodes, extrathyroidal extension, histologic subtype, and the patient’s age and overall health.
This is one of the most important reasons to see an endocrinologist who specializes in thyroid cancer management after surgery, rather than a general internist or a physician who manages thyroid disease only occasionally.
Because the RAI decision in intermediate-risk patients is genuinely contested among experts, seeking a second opinion from a thyroid cancer specialist before agreeing to treatment is not only reasonable but encouraged. If your physician discourages a second opinion on this topic, that itself is useful information.
Questions to Ask Before Agreeing to RAI
- What risk category does my cancer fall into? Low, intermediate, or high risk — and what specific pathology features place it there.
- What is the evidence for RAI benefit in my specific risk category? Ask directly whether the benefit is well-established or an area of genuine clinical uncertainty.
- What are the potential downsides of RAI for me specifically? Salivary gland effects, secondary cancer risk with higher doses, fertility considerations.
- What happens to my monitoring and follow-up if I do not have RAI? Understanding the surveillance plan without RAI helps you weigh the tradeoff.
- Would you recommend a second opinion given the uncertainty in my case?
The Bottom Line
Radioactive iodine is a valuable tool for patients who genuinely need it. For high-risk disease it is an important part of comprehensive treatment. For very low-risk disease the current evidence argues against it. For everyone in between, the honest answer is that it depends — and the physician best positioned to make that call is an experienced thyroid cancer endocrinologist. Do not agree to RAI or decline it based on a single conversation with a non-specialist.
References
- Haugen BR, et al. 2015 ATA Management Guidelines for Thyroid Nodules and DTC. Thyroid. 2016.
- American Thyroid Association — Radioactive Iodine.
- National Cancer Institute — Thyroid Cancer Treatment.
This article was written by John P. Sabra, MD FACS and is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. The decision about radioactive iodine therapy is individualized and should be made collaboratively with the specialists managing your care.
More from the Advanced Thyroid Care series
Ready to Talk to a Specialist?
A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.
Find a Thyroid Specialist Near You →